Loading patent…
AssigneesThe Regents of the University of California, U.S. Government as represented by the Department of Veterans Affairs
InventorsMichael George Shlipak, Michelle Estrella, Joachim H. Ix, Rebecca Scherzer
Estimating the term…
The present disclosure provides methods of determining whether a subject treated for hypertension should continue hypertension treatment. In exemplary embodiments, the method comprises measuring the level of at least two of the following in a urine sample obtained from the subject: (i) Alpha-1 microglobulin (aim); (ii) kidney injury molecule (KIM-1); and (iii) Chitinase-3-like protein (YKL-40); wherein the subject should continue the hypertension treatment, when the levels are decreased or unchanged, relative to a control level, and wherein the subject should discontinue or decrease the hypertension treatment, when the levels are increased, relative to a control level. Related methods, kits, assay systems, systems comprising machine readable instructions, computer-readable storage media, and methods implemented by a processor in a computer are furthermore provided herein.
A method of treating a subject with hypertension, wherein the subject is on an intense hypertension treatment comprising an ACE inhibitor or an angiotensin II receptor blocker, wherein the subject was not known to have a kidney disease at the time hypertension treatment began, the method comprising (a) determining levels of Alpha-1 microglobulin (α1m) and kidney injury molecule (KIM-1) in a urine sample from the subject receiving the hypertension treatment, and (b) decreasing the hypertension treatment when the levels of α1m and KIM-1 are increased in a urine sample obtained from the subject relative to a matched control subject known to have hypertension but has not been treated for hypertension.
Dependencies are inferred from the claim text.